ProShares UltraShort Bloomberg Natural Gas ETF vs Twist Bioscience Corp — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.65 (market cap $141.25M), while Twist Bioscience Corp trades at $161.65 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 71.4× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days and Twist Bioscience Corp for 27 Days on average.
| KOLD | TWST | |
|---|---|---|
Market Cap | $141.25M | $10.08B |
Volume | 5,492,367 | 4,229,037 |
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $205.00 |
52-Week Low | $13.58 | $25.45 |
Typical Hold Time | 10 Days | 27 Days |
Enterprise Value | — | $10.01B |
Signals from Pluang's Aura AI — not financial advice
KOLD is trading at $24.475, down 1.47% on the day, with a bearish technical outlook as moving averages signal strong selling pressure. The stock faces headwinds from record-high natural gas production and mild weather forecasts that are weighing on energy sector sentiment. Recent news highlights geopolitical tensions in the Middle East and supply dynamics affecting natural gas markets, creating volatility for energy-related investments.
The outlook remains cautious given the bearish technical indicators and fundamental pressures from oversupply conditions in natural gas markets. Investment opportunities exist for contrarian investors betting on geopolitical risk premiums, but risks include continued production growth and weather-dependent demand uncertainty that could pressure energy sector performance in the near term.
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →